Categories: News

Caladrius Biosciences to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 22, 2022, at 4:30 p.m. Eastern Time

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BASKING RIDGE, N.J., March 15, 2022 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that the Company will report its financial results for the three months and twelve months ended December 31, 2021, on Tuesday, March 22, 2022, at 4:30 p.m. (ET). To join the live conference call, please refer to the dial-in information provided below.

Dial-in information:
Conference ID: 5066195
U.S. Toll-Free: 866-595-8403
International: 706-758-9979

Please dial-in 10 minutes before the start of the conference call.

A live webcast of the call will also be accessible under the Investors & News section of the Caladrius website (https://ir.caladrius.com) and will be available for replay for 90 days after the conclusion of the call.

For those unable to participate on the live conference call, an audio replay will be available that day starting at 7:30 p.m. (ET) until March 29, 2022, by dialing 855-859-2056 (U.S. Toll-Free) or 404-537-3406 (International) and by entering the replay passcode: 5066195.

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

The Company’s current product candidates include: XOWNA® (CLBS16), the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study (www.freedom-trial.com) in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS12 (HONEDRA® in Japan), recipient of orphan designation for Buerger’s Disease in the U.S. and, in Japan, recipient of a SAKIGAKE designation and eligible for early conditional approval for the treatment of CLI and Buerger’s Disease based on the results of an ongoing clinical trial; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for DKD. For more information on the Company, please visit www.caladrius.com.

Contact:

Investors:
Caladrius Biosciences, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@caladrius.com

 

Staff

Recent Posts

CloudWave Ranked #15 on Channel Partners 2025 MSP 501—The Tech Industry’s Most Prestigious List of Managed Service Providers Worldwide

MARLBOROUGH, Mass.--(BUSINESS WIRE)--CloudWave, a leading provider of integrated cybersecurity and cloud infrastructure solutions, has been…

33 minutes ago

CloudWave Ranked #15 on Channel Partners 2025 MSP 501—The Tech Industry’s Most Prestigious List of Managed Service Providers Worldwide

MARLBOROUGH, Mass.--(BUSINESS WIRE)--CloudWave, a leading provider of integrated cybersecurity and cloud infrastructure solutions, has been…

35 minutes ago

Availity Applauds Industry Commitment to Modernize Authorizations

Availity’s Intelligent Utilization Management delivers on health plans’ ambitious visionJACKSONVILLE, Fla.--(BUSINESS WIRE)--Availity, the nation’s largest…

36 minutes ago

LevelJump Announces 2025 First Quarter Results; Anticipates Revocation of Cease Trade Order

Toronto, Ontario--(Newsfile Corp. - June 23, 2025) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the…

40 minutes ago

Agentic AI Startup VoiceCare AI Completes Successful Funding Round

Company closes $4.54M in Seed round led by Caduceus Capital Partners, with participation from Bread…

40 minutes ago

TOBY Urine Test completes participation in 2025 Mayo Clinic and ASU Alliance for Health Care MedTech Accelerator

BOSTON, June 23, 2025 /PRNewswire/ -- TOBY, Inc., a biotechnology company focusing on improving early…

40 minutes ago